Pharma companies want clarity on supplementary data in China
Despite the Supreme Court’s proposal to lower the bar for post-filing patent data, innovators are sceptical that the provisions will have real impact
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: